Catalyst Pharmaceuticals Inc (NASDAQ:CPRX)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a research report issued to clients and investors on Monday. They currently have a $6.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s target price points to a potential upside of 261.45% from the stock’s previous close.
Separately, Zacks Investment Research cut shares of Catalyst Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, January 5th.
Shares of Catalyst Pharmaceuticals (NASDAQ:CPRX) traded up 7.79% during mid-day trading on Monday, hitting $1.66. The stock had a trading volume of 3,994,589 shares. The stock’s market capitalization is $137.56 million. Catalyst Pharmaceuticals has a 12-month low of $0.51 and a 12-month high of $1.81. The stock’s 50-day moving average price is $1.17 and its 200-day moving average price is $1.14.
Catalyst Pharmaceuticals (NASDAQ:CPRX) last posted its quarterly earnings data on Wednesday, March 15th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.02. On average, equities analysts anticipate that Catalyst Pharmaceuticals will post ($0.26) EPS for the current fiscal year.
Your IP Address:
Several hedge funds have recently modified their holdings of CPRX. Royal Bank of Canada acquired a new stake in shares of Catalyst Pharmaceuticals during the second quarter valued at approximately $117,000. Berson & Corrado Investment Advisors LLC boosted its stake in shares of Catalyst Pharmaceuticals by 76.1% in the third quarter. Berson & Corrado Investment Advisors LLC now owns 181,900 shares of the biopharmaceutical company’s stock valued at $198,000 after buying an additional 78,600 shares during the last quarter. Baker BROS. Advisors LP acquired a new stake in shares of Catalyst Pharmaceuticals during the third quarter valued at approximately $5,561,000. Finally, Kingdon Capital Management L.L.C. acquired a new stake in shares of Catalyst Pharmaceuticals during the fourth quarter valued at approximately $794,000. Institutional investors own 28.13% of the company’s stock.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.
Receive News & Ratings for Catalyst Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.